The breakthrough designation is based on data from the expansion cohort of a Phase I/II study evaluating sacituzumab tirumotecan in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.
FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for Metastatic Nonsquamous Non-Small Cell Lung Cancer
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours